• For Patients and Caregivers
• For Health Care Professionals
• For Renal Dietitians

• Home
• Partnering With Patients
  • Talking to Your Patients
• Collaborating With Colleagues
• About FOSRENOL^®
  • Efficacy
  • Safety
  • Dosing
  • Preference
  • Tolerability
  • FOSRENOL FAQs
• Renal Resources
  • Clinic Corner
  • A Delicate Balance
  • Exclusive Offers
  • The FOSRENOL^® Focus
  • Helpful Links
• Patient Assistance Program
• The Community Bulletin Program

Important Safety Information

• The most common adverse events were gastrointestinal, such as nausea and vomiting, and generally abated over time with continued dosing
• The most common side effects leading to discontinuation in clinical trials were gastrointestinal events (nausea, vomiting, and diarrhea)
• Other side effects reported in trials included dialysis graft complications, headache, abdominal pain, and hypotension
• Although studies were not designed to detect differences in risk of fracture and mortality, there were no differences demonstrated in patients treated with FOSRENOL^® compared to alternative therapy for up to 3 years
• The duration of treatment exposure and time of observation in the clinical program were too short to conclude that FOSRENOL^® does not affect the risk of fracture or mortality beyond 3 years
• While lanthanum has been shown to accumulate in the GI tract, liver, and bone in animals, the clinical significance in humans is unknown
• Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL^® clinical studies. Caution should be used in patients with these conditions
• FOSRENOL^® should not be taken by patients who are nursing or pregnant
• FOSRENOL^® should not be taken by patients who are under 18 years of age

FOSRENOL^® is indicated to reduce serum phosphate in patients with end-stage renal disease.

* Maintenance of reduction was observed for up to 3 years in patients treated with FOSRENOL^®.

Send to a Colleague